Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (379)	10/28/1998 5:47:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 717

biz.yahoo.com The roto-rooter presentations are coming in two weeks.

To: tnsaf who wrote (379)	11/4/1998 10:59:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 717

Jason, Abstract #2071: "Pharmacokinetics of the Radiation Sensitizer Gadolinium Texaphyrin in a Phase Ib/II Trial for Patients with Brain Metastases Receiving Whole Brain Radiation" Abstract #2072: "Selective Uptake and Retention of the Radiation Sensitizer Gadolinium Texaphyrin (Gd-Tex) in Tumors Demonstrated by MRI in Phase I and II Clinical Trials" PCYC faxed me copies of the 2 poster presentations from the ASTRO conference. They were pretty small print and didn't fax great, but here is what I was able to figure out that was of interest. Short plasma half-life (good). Pharmokinetics seemed straightforward, although as near as I could figure out they mostly showed simulations rather than actual data. Little concentration in non-tumor tissue except for liver and kidney, where there was substantial concentration (as shown by MRI). Undisclosed how long it stayed in kidney/liver. May mean can't use it for tumors near liver/kidney (my comment). Clear concentration in tumors at reasonable dose levels. Significantly, this tumor concentration apparently occurred in both primary tumor and in mets, in all tumor types evaluated, and in non-brain tissue as well as brain. Concentration in tumors after repeated doses was long-lived - up to 56 days - so maybe you can just wait if tumors are in liver/kidney vicinity and give the radiation later. This may also turn out to be significant for chemo/Gd-Tex combinations. Multiple dosing sometimes revealed multiple small brain metastases that didn't show up on initial MRI - may mean that surgery not a good choice and radiation (+ GD-TEX of course) better. Bottom line: Looks to me that if Gd-Tex works for brain mets, it will also work for other tumor locations and types. ---- Nice recovery in the stock price. MRVT has also recovered, and MRVT's moves seem to influence PCYC (although it shouldn't really, because PDT for cancer is not what is going to ultimately drive PCYC). Peter